+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 106 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are studying the use of unlicensed cryopreserved cord blood units CBUs for transplantation in both children and adults with blood cancers and other related disorders. This observational study involves patients with hematologic malignancies and various inherited and acquired disorders affecting the blood and immune system. The main goal is to monitor how well neutrophil recovery occurs after transplantation using these unlicensed CBUs in multiple institutions. Participants receive unlicensed cryopreserved CBUs as part of their transplant treatment. The study includes patients of any age receiving these CBUs for approved indications. The protocol focuses on the access and distribution of these unlicensed units rather than a specific treatment intervention. The study gathers data from recipients who receive these CBUs, tracking outcomes after transplantation. Participants are monitored for neutrophil recovery at 60 and 100 days after transplant, defined by a neutrophil count of at least 500mm3. Researchers also collect information on infection transmission, infusion reactions, survival rates at one year, and incidence of acute and chronic graft versus host disease. Platelet recovery is also evaluated. Safety and efficacy outcomes are followed over time to better understand the effects of unlicensed CBUs in this patient population.

All AgesAll Genders
142 locations
P

Actively Recruiting

Researchers are evaluating tabelecleucel, an allogeneic T-cell immunotherapy, for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disease EBV PTLD in patients after failure of rituximab or rituximab plus chemotherapy. This phase 3, multicenter, open-label trial focuses on participants who have undergone solid organ transplant or allogeneic hematopoietic cell transplant and whose disease has not responded to prior standard treatments. Participants receive intravenous tabelecleucel in 5-week cycles, with doses given on Days 1, 8, and 15 of each cycle, followed by observation through Day 35. Treatment continues until the participant achieves a maximal response, experiences unacceptable side effects, starts other therapies, or fails the tabelecleucel treatment. The study includes different cohorts based on transplant type and prior therapies, and all participants have confirmed availability of partially HLA-matched tabelecleucel. Throughout the study, participants undergo assessments including PET-CT or MRI scans to evaluate disease status, with additional brain imaging if central nervous system involvement exists. Researchers monitor response rates, duration of response, overall survival, and safety events such as allograft loss or rejection over a follow-up period of up to five years. Participants are observed closely to understand the benefits and risks of tabelecleucel in this condition.

All AgesAll GendersPhase 3
71 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating the best way to combine chemotherapy and radiation therapy for children and young adults with localized non-germinomatous germ cell tumors NGGCT in the brain. The study aims to optimize radiation treatment for patients who respond well to initial chemotherapy and to use higher dose chemotherapy followed by radiation for those who do not respond as well. This phase II trial focuses on how tumors respond to initial chemotherapy to decide the next treatment steps, aiming to reduce side effects and improve disease control. Participants receive induction chemotherapy with drugs like carboplatin, etoposide, ifosfamide, and thiotepa over up to six cycles, repeated every 21 days if no disease progression occurs. Based on their response, patients are assigned to one of two plans Plan A involves radiation therapy to the ventricles and spinal canal WVSCI, while Plan B includes high-dose chemotherapy with stem cell transplant followed by craniospinal radiation. Some patients may undergo second-look surgery to guide treatment decisions. During the study, participants have MRIs, cerebrospinal fluid and blood samples collected, and complete questionnaires assessing cognitive and behavioral functions. Researchers monitor tumor response, progression-free survival, overall survival, and side effects over up to 10 years. The study also compares outcomes based on radiation type and its effects on growth and blood counts, aiming to improve long-term quality of life for patients.

Age: 3Years - 29YearsAll GendersPhase 2
170 locations
E

Actively Recruiting

Researchers are evaluating combination chemotherapy treatments for patients with newly diagnosed diffuse anaplastic Wilms tumors DAWT and relapsed favorable histology Wilms tumors FHWT. This phase II trial aims to compare different chemotherapy regimens to see if adding drugs like vincristine and irinotecan improves survival outcomes for these patients, based on historical data. The study also explores kidney toxicity, genetic factors, and surgical outcomes related to these tumors. Patients are assigned to one of two treatment groups. Arm I Regimen UH-3 involves multiple cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan administered intravenously every 21 days with radiation therapy as needed. Arm II Regimen ICECycloTopo includes cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan given intravenously every 21 days with surgery andor radiation as clinically indicated. Both groups undergo various imaging scans and biopsies throughout treatment. Participants are closely monitored with CT, PET, X-rays, MRI, ultrasound, bone scans, blood tests, and biopsies during the trial. After treatment, follow-up visits occur every 3 months for the first two years, then every 6 months for years 3 and 4, and once at year 5. The primary outcomes measured are event-free survival and overall survival up to five years. The study also collects blood, urine, and tumor tissue samples for future research and monitors treatment side effects and kidney function.

Age: 0 - 30YearsAll GendersPhase 2
205 locations
E

Actively Recruiting

Researchers are evaluating how well a lower dose of radiotherapy after chemotherapy works to treat children and young adults with central nervous system CNS germinomas. This Phase II study focuses on using carboplatin and etoposide chemotherapy followed by reduced radiation doses to see if this approach can effectively control the disease while potentially reducing long-term side effects. The study also investigates neuroendocrine function and cognitive processing speed as important outcomes. Participants receive up to four cycles of chemotherapy with carboplatin given intravenously on day 1 and etoposide given intravenously on days 1 through 3 every 21 days. After chemotherapy, patients are assigned to different treatment groups based on their response and tumor characteristics. Radiation therapy options include 3-dimensional conformal radiation, intensity-modulated radiation, or proton therapy with varying doses depending on the specific group. Some patients may undergo second-look surgery to assess tumor response. Blood, cerebrospinal fluid, and tissue samples may be collected throughout the study for further research. During the study, participants undergo regular magnetic resonance imaging MRI scans and may have lumbar punctures for cerebrospinal fluid collection during screening and follow-up. They are monitored for event-free survival, overall survival, tumor response, neuroendocrine function, and cognitive processing speed over several years. Follow-up visits occur every 3 months for the first year, then every 4 months for two years, followed by annual visits for up to 10 years after treatment. This allows researchers to assess long-term effects and outcomes.

Age: 3Years - 29YearsAll GendersPhase 2
115 locations
C

Actively Recruiting

Researchers are comparing the effectiveness of two combinations of drugs, teclistamab with daratumumab and lenalidomide Tec-DR, and talquetamab with daratumumab and lenalidomide Tal-DR, against the combination of daratumumab, lenalidomide, and dexamethasone DRd in adults with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. This Phase 3 trial focuses on evaluating treatment outcomes and survival rates over an extended period. Participants will be randomly assigned to one of three groups one receiving teclistamab by subcutaneous injection combined with daratumumab and oral lenalidomide another receiving talquetamab by subcutaneous injection combined with daratumumab and lenalidomide and the third receiving daratumumab by subcutaneous injection along with oral lenalidomide and dexamethasone, which may be given orally or intravenously. Treatments will be administered according to protocol, with close monitoring throughout the study. During the study, participants will undergo regular evaluations over up to nine years, including assessments of disease progression, survival, response to treatment, and quality of life using various questionnaires. Safety will be monitored through laboratory tests, physical exams, vital signs, electrocardiograms, and tracking of any adverse events. Researchers will also measure drug concentrations and immune responses to the study drugs. Participation may last until disease progression, death, or the end of the study period.

Age: 18Years +All GendersPhase 3
270 locations
E

Actively Recruiting

Researchers are studying the safety, tolerability, how the body processes, and preliminary anti-cancer effects of Tulmimetostat DZR123, alone and combined with enzalutamide, in adults with advanced solid tumors and lymphomas. This open-label Phase 12 trial aims to find appropriate dosing and examine the treatments effects across various tumor types, including specific genetic mutations and metastatic prostate cancer. The study has two main phases. Phase 1 involves dose escalation of Tulmimetostat alone to find the maximum tolerated and recommended doses. Phase 2 expands into multiple disease-specific groups receiving Tulmimetostat monotherapy or combination therapy with enzalutamide, including dose optimization and food-effect evaluations. Treatments are given orally once daily in 28-day cycles. The combination phase includes a dose escalation part and a larger dose expansion part to further assess safety and activity. Participants will undergo safety monitoring, lab tests, tumor evaluations, and biomarker sample collections throughout the study. Follow-up continues for up to 30 months to assess response and survival, with ongoing monitoring for second primary cancers every 3 months for the first 3 years, then every 6 months. Researchers measure dose-limiting toxicities, response rates, prostate-specific antigen changes, and other pharmacokinetic and pharmacodynamic outcomes to evaluate treatment effects and safety.

Age: 18Years +All GendersPhase 1Phase 2
80 locations
C

Actively Recruiting

Researchers are evaluating the effects of nivolumab combined with blinatumomab compared to blinatumomab alone in patients with first relapse B-cell acute lymphoblastic leukemia B-ALL, including those with Down syndrome. This phase II trial aims to assess event-free survival and safety in children and young adults aged 1 to under 31 years. The study also explores remission rates and adverse events related to these treatments. Participants receive different combinations of blinatumomab, nivolumab, dexamethasone, methotrexate, and other chemotherapy drugs depending on their assigned group or arm. Treatment cycles generally last 36 to 37 days and may repeat up to two cycles if no disease progression or unacceptable toxicity occurs. Additional therapies like radiation and intrathecal chemotherapy are given based on disease characteristics. Down syndrome patients have a specific treatment arm with tailored medication schedules. Throughout the study, participants undergo lumbar punctures, bone marrow biopsies and aspirations, and collection of blood, urine, and cerebrospinal fluid for monitoring. Follow-up visits occur every three months for one year after treatment completion to assess outcomes such as minimal residual disease negative remission and event-free survival. Safety and tolerability are closely monitored during therapy and follow-up.

Age: 1Year - 30YearsAll GendersPhase 2
227 locations
C

Actively Recruiting

Researchers are investigating treatments for newly diagnosed acute myeloid leukemia AML in children and young adults, with or without mutations in the FLT3 gene. This Phase III trial compares standard chemotherapy, which includes daunorubicin, cytarabine, and gemtuzumab ozogamicin, to therapy using a special formulation called CPX-351, which contains daunorubicin and cytarabine designed to stay longer in the bone marrow. The study also evaluates adding gilteritinib, a drug that may block abnormal FLT3 gene function and slow cancer growth, especially in patients with FLT3 mutations. The goals include comparing treatment effects, studying heart function during therapy, and assessing neurocognitive outcomes. Participants receive treatment based on risk groups and FLT3 mutation status, assigned to different study arms. Treatments include various combinations of chemotherapy drugs given intravenously, intrathecally, or orally, such as CPX-351, daunorubicin, cytarabine, gemtuzumab ozogamicin, dexrazoxane, etoposide, mitoxantrone, and gilteritinib. Treatment phases include induction, intensification, and for some, hematopoietic stem cell transplantation HSCT. Intrathecal therapies address central nervous system involvement. Gilteritinib is administered orally over extended periods in certain groups. The study also involves optional neurocognitive testing. Throughout the study, participants undergo regular assessments including blood and bone marrow samples, imaging scans like MRI and PET, and cardiac function tests such as echocardiograms. Researchers monitor minimal residual disease, survival rates, heart health, and neuropsychological function. Safety and adverse events are tracked up to three years, with some patients receiving long-term gilteritinib maintenance. The overall participation may last several years, allowing detailed evaluation of treatment impact and side effects.

Age: 6Months - 21YearsAll GendersPhase 3
206 locations

1-10 of 106

1